Innorna secures dual FDA designations for Wilson’s disease mRNA therapy
The US Food and Drug Administration (FDA) has granted rare paediatric disease and orphan drug designations for IN013, Innorna's mRNA…
All articles by Robert Barrie
Robert Barrie
Robert Barrie is a news and features reporter for Pharmaceutical Technology and Medical Device Network. Robert holds a BSc in Neuroscience and holds interests in neurological devices, infectious diseases, and company investment such as initial public offerings (IPOs). Contact Rob
-
-
FDA free to pursue semaglutide compounders after latest court ruling
A US judge has rejected efforts by a compounded drugs industry group to keep making an alternative version of Novo…
-
Thermo Fisher counters tariffs with $2bn investment into US manufacturing
Thermo Fisher has outlaid $2bn to expand manufacturing and development in the US, joining the long list of companies directing…
-
Eli Lilly sues Mochi Health and others for ‘deceptive’ tirzepatide marketing
Eli Lilly has filed a lawsuit against four telehealth platforms selling compounded versions of its blockbuster metabolic disorder drug tirzepatide,…
-
KKR offers $1.2bn to buy Swedish life sciences group Biotage
Private equity firm KKR has offered to buy all shares in Swedish life sciences company Biotage for Skr11.6bn ($1.2bn). The…
-
Big pharma pushes for European policy change as tariffs loom
Pharmaceutical companies are demanding changes in European regulation as looming tariffs implemented by US President Donald Trump "threaten" billions of…
-
WHO member states agree on treaty to fight future pandemics
Member states of the World Health Organization (WHO) have reached an agreement on how to tackle future pandemics courtesy of…
-
The GLP-1 drug shortage is over. What’s next for the compounders?
“I am taking compounded semaglutide that I ordered online, but I don’t know how long I will have access to…
-
Scancell shares up 6% after NHS partnership for fast-track cancer vaccine trial
Patients with an advanced type of skin melanoma in England will be given expedited access to a new vaccine being…
-
AstraZeneca’s oral breast cancer drug Truqap greenlit for NHS use
AstraZeneca’s Truqap (capivasertib) has been approved for use by the National Health Service (NHS) in England and Wales, providing a…